Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol ELU42 01 01: Phase I/IIA, Open Label, Single Arm Evaluation of Topical ELU42 (XAV939 in DHA77) for Wagner Grade 1-2 Diabetic Foot Ulcers

NCT07396376 is registered in ClinicalTrials.gov with Eluciderm Inc as lead sponsor.

NCT NCT07396376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07396376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol ELU42 01 01: Phase I/IIA, Open Label, Single Arm Evaluation of Topical ELU42 (XAV939 in DHA77) for Wagner Grade 1-2 Diabetic Foot Ulcers
Lead sponsor
Eluciderm Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 10, 2025
Completion date
June 1, 2026
Enrollment
15 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic wound, diabetic foot ulcer, open wound, wagner grade 1 - 2